Douglas Lorne Arnold, MD, FRCP(C)

Zitiert von

	Alle	Seit 2016
Zitate	41830	15960
h-index	109	54
i10-index	346	240

3600

1800

900

2700

1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021165 138 183 216 304 287 434 511 662 812 1033 1099 1051 1160 1279 1127 1230 1245 1296 1337 1358 1630 1897 2145 2256 2517 2926 2985 3148 3517 754

Koautoren

Sridar Narayanan, PhDAssistant Professor: Department of Neurology and Neurosurgery, McGill UniversityBestätigte E-Mail-Adresse bei mcgill.ca
Amit Bar-OrProfessor, University of PennsylvaniaBestätigte E-Mail-Adresse bei pennmedicine.upenn.edu
Paul M. MatthewsEdmond and Lily Safra Chair, Professor of Clinical Neurosciences, Imperial College LondonBestätigte E-Mail-Adresse bei imperial.ac.uk
D. Louis CollinsProfessor of Biomedical Engineering and Neurology & Neurosurgery, McGill UniversityBestätigte E-Mail-Adresse bei mcgill.ca
Nicola De StefanoProfessor of Neurology, Universtiy of Siena,Bestätigte E-Mail-Adresse bei unisi.it
Zografos CaramanosMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill UniversityBestätigte E-Mail-Adresse bei mcgill.ca
Fernando CendesFull Professor, Department of Neurology, FCM, University of Campinas - UNICAMPBestätigte E-Mail-Adresse bei unicamp.br
Gavin GiovannoniBarts and The London School of Medicine and DentistryBestätigte E-Mail-Adresse bei giovannoni.net
Jerry S Wolinsky, MDProfessor Emeritus Neurology, McGovern Medical School, UTHealth, The University of Texas HealthBestätigte E-Mail-Adresse bei uth.tmc.edu
eric shoubridgeProfessor, Human Genetics, McGill UniversityBestätigte E-Mail-Adresse bei ericpc.mni.mcgill.ca
Li Min LiProfessor of Neurology, Faculty of Medical Sciences at University of CampinasBestätigte E-Mail-Adresse bei fcm.unicamp.br
Jeffrey A CohenCleveland ClinicBestätigte E-Mail-Adresse bei ccf.org
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicBestätigte E-Mail-Adresse bei ccf.org
Bruce PikeCAIP Chair in Healthy Brain Aging, Hotchkiss Brain Institute, University of CalgaryBestätigte E-Mail-Adresse bei ucalgary.ca
John G. SledSenior Scientist, Hospital for Sick Children / Professor, University of TorontoBestätigte E-Mail-Adresse bei utoronto.ca
Carmela TartagliaAssociate Professor, University of TorontoBestätigte E-Mail-Adresse bei uhn.ca
Massimo FilippiSan Raffaele Scientific Institute, Vita-Salute San Raffaele UniversityBestätigte E-Mail-Adresse bei hsr.it
Robert A BrownUniversity of Calgary; Montreal Neurological InstituteBestätigte E-Mail-Adresse bei mcgill.ca
Alasdair ColesUniversity of CambridgeBestätigte E-Mail-Adresse bei medschl.cam.ac.uk
Emmanuelle WaubantProfessor of Neurology and PediatricsBestätigte E-Mail-Adresse bei ucsf.edu

Douglas Lorne Arnold, MD, FRCP(C)

James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGill

Bestätigte E-Mail-Adresse bei mcgill.ca - Startseite

Magnetic Resonance Imaging Neurological Disorders Multiple Sclerosis Alzheimer's Disease


Titel Nach Zitationen sortieren Nach Jahr sortieren Nach Titel sortieren	Zitiert von Zitiert von	Jahr
B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008	2150	2008
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012	1502	2012
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... N Engl J Med 376 (3), 209-220, 2017	956	2017
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012	932	2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012	929	2012
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... N Engl J Med 376 (3), 221-234, 2017	848	2017
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy MC Preul, Z Caramanos, DL Collins, JG Villemure, R Leblanc, A Olivier, ... Nature medicine 2 (3), 1996	627	1996
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability N De Stefano, S Narayanan, GS Francis, R Arnaoutelis, MC Tartaglia, ... Archives of neurology 58 (1), 65-70, 2001	588	2001
Imaging axonal damage of normal-appearing white matter in multiple sclerosis L Fu, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, ... Brain 121 (1), 103-113, 1998	559	1998
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study N De Stefano, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, ... Brain 121 (Pt 8), 1469-1477, 1998	554	1998
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR DL Arnold, PM Matthews, GK Radda Magnetic resonance in medicine 1 (3), 307-315, 1984	527	1984
Reversible decreases in N‐acetylaspartate after acute brain injury ND Stefano, PM Matthews, DL Arnold Magnetic Resonance in Medicine 34 (5), 721-727, 1995	500	1995
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region N Bernasconi, A Bernasconi, Z Caramanos, SB Antel, F Andermann, ... Brain 126 (2), 462-469, 2003	482	2003
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008	464	2008
Energetics of human muscle: exercise-induced ATP depletion DJ Taylor, P Styles, PM Matthews, DL Arnold, DG Gadian, P Bore, ... Magn Reson Med 3 (1), 44-54, 1986	368	1986
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques DL Arnold, PM Matthews, GS Francis, J O'Connor, JP Antel Annals of Neurology: Official Journal of the American Neurological …, 1992	365	1992
Chemical pathology of acute demyelinating lesions and its correlation with disability N De Stefano, PM Matthews, JP Antel, M Preul, G Francis, DL Arnold Annals of neurology 38 (6), 901-909, 1995	363	1995
Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis H Reddy, S Narayanan, R Arnoutelis, M Jenkinson, J Antel, PM Matthews, ... Brain 123 (11), 2314-2320, 2000	351	2000
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P ... Lancet 391 (10127), 1263-1273, 2018	350	2018
Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease DL Arnold, PM Matthews, G Francis, J Antel Magnetic resonance in medicine 14 (1), 154-159, 1990	345	1990

Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.

Artikel 1–20

Zitate pro Jahr

Doppelte Zitate

Zusammengeführte Zitate

Koautor hinzufügenKoautoren

PDF hochladen

Diesem Autor folgen

Zitiert von

Koautoren